Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection

Stock News12-01

Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as "Henlius") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121426684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121426684","market":"hk","top_or_hot":-1,"title":"Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection","media":"Stock News","content":"<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1121426684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121426684","pubTimestamp":1764580217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0060":"抗癌","BK0187":"一线龙头","BK0175":"白马股","BK0028":"国家队","BK0239":"医药制造","BK0012":"证金概念","BK0183":"MSCI概念","02196":"复星医药","BK1191":"制药","BK0188":"融资融券","BK1515":"抗疫概念","BK1593":"医美概念股","BK0096":"民营医院","BK0196":"行业龙头"},"translate_title":"复星医药（600196.SH）子公司HLX37注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled entities (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration for the clinical trial of HLX37 injection (a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in treating patients with advanced/metastatic solid tumors. Henlius plans to initiate a Phase I clinical trial for HLX37 in China once conditions are met. HLX37 is a self-developed recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody by the group, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies to date have demonstrated HLX37's ability to inhibit tumor growth with favorable safety profiles.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121426684","isCrawlerRequest":true}